Drug intelligence / Profile preview

BX-E001

Development stage: Unknown
Lead developer: Baylx
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

BX-E001 is a bacteriophage cocktail developed by BiomX, designed to specifically target and lyse *Klebsiella pneumoniae* (Kp) strains associated with the pathogenesis of Primary Sclerosing Cholangitis (PSC) and Inflammatory Bowel Disease (IBD). The therapy utilizes BiomX's proprietary BOLT (Bacteriophage Optimization Lead Targeting) platform to identify and optimize phages with high host range and low resistance potential. By selectively eliminating these pro-inflammatory bacteria while sparing the rest of the gut microbiome, BX-E001 aims to reduce liver inflammation and disease progression. The program has transitioned into clinical development under the designations BX002 and BX003.

Other names: Klebsiella pneumoniae phage cocktail

Beyond the preview

Go deeper on BX-E001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BX-E001.

Explore the full profile